These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 12392734

  • 1. Identification of novel inhibitors of fibroblast growth factor (FGF-2) binding to heparin and endothelial cell survival from a structurally diverse carbohybrid library.
    Murphy PV, Pitt N, O'Brien A, Enright PM, Dunne A, Wilson SJ, Duane RM, O'Boyle KM.
    Bioorg Med Chem Lett; 2002 Nov 18; 12(22):3287-90. PubMed ID: 12392734
    [Abstract] [Full Text] [Related]

  • 2. Synthesis of a glucuronic acid and glucose conjugate library and evaluation of effects on endothelial cell growth.
    Pitt N, Duane RM, O'Brien A, Bradley H, Wilson SJ, O'Boyle KM, Murphy PV.
    Carbohydr Res; 2004 Aug 02; 339(11):1873-87. PubMed ID: 15261580
    [Abstract] [Full Text] [Related]

  • 3. Synthesis of disaccharides derived from heparin and evaluation of effects on endothelial cell growth and on binding of heparin to FGF-2.
    O'Brien A, Lynch C, O'Boyle KM, Murphy PV.
    Carbohydr Res; 2004 Oct 04; 339(14):2343-54. PubMed ID: 15388349
    [Abstract] [Full Text] [Related]

  • 4. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
    Casu B, Guerrini M, Guglieri S, Naggi A, Perez M, Torri G, Cassinelli G, Ribatti D, Carminati P, Giannini G, Penco S, Pisano C, Belleri M, Rusnati M, Presta M.
    J Med Chem; 2004 Feb 12; 47(4):838-48. PubMed ID: 14761186
    [Abstract] [Full Text] [Related]

  • 5. Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction.
    Plum SM, Vu HA, Mercer B, Fogler WE, Fortier AH.
    Immunopharmacol Immunotoxicol; 2004 Feb 12; 26(1):29-41. PubMed ID: 15106730
    [Abstract] [Full Text] [Related]

  • 6. Development of a high throughput screening assay for inhibitors of fibroblast growth factor-receptor-heparin interactions.
    Aviezer D, Seddon AP, Wildey MJ, Böhlen P, Yayon A.
    J Biomol Screen; 2001 Jun 12; 6(3):171-7. PubMed ID: 11689113
    [Abstract] [Full Text] [Related]

  • 7. alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells.
    Rusnati M, Tanghetti E, Dell'Era P, Gualandris A, Presta M.
    Mol Biol Cell; 1997 Dec 12; 8(12):2449-61. PubMed ID: 9398667
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
    Hagedorn M, Zilberberg L, Wilting J, Canron X, Carrabba G, Giussani C, Pluderi M, Bello L, Bikfalvi A.
    Cancer Res; 2002 Dec 01; 62(23):6884-90. PubMed ID: 12460903
    [Abstract] [Full Text] [Related]

  • 13. Possible mechanism for lead inhibition of vascular endothelial cell proliferation: a lower response to basic fibroblast growth factor through inhibition of heparan sulfate synthesis.
    Fujiwara Y, Kaji T.
    Toxicology; 1999 Apr 15; 133(2-3):147-57. PubMed ID: 10378481
    [Abstract] [Full Text] [Related]

  • 14. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound.
    Miao HQ, Ornitz DM, Aingorn E, Ben-Sasson SA, Vlodavsky I.
    J Clin Invest; 1997 Apr 01; 99(7):1565-75. PubMed ID: 9120000
    [Abstract] [Full Text] [Related]

  • 15. Sulfated malto-oligosaccharides bind to basic FGF, inhibit endothelial cell proliferation, and disrupt endothelial cell tube formation.
    Foxall C, Wei Z, Schaefer ME, Casabonne M, Fugedi P, Peto C, Castellot JJ, Brandley BK.
    J Cell Physiol; 1996 Sep 01; 168(3):657-67. PubMed ID: 8816920
    [Abstract] [Full Text] [Related]

  • 16. Two hierarchies of FGF-2 signaling in heparin: mitogenic stimulation and high-affinity binding/receptor transphosphorylation.
    Krufka A, Guimond S, Rapraeger AC.
    Biochemistry; 1996 Aug 27; 35(34):11131-41. PubMed ID: 8780517
    [Abstract] [Full Text] [Related]

  • 17. Endothelial proteoglycans inhibit bFGF binding and mitogenesis.
    Forsten KE, Courant NA, Nugent MA.
    J Cell Physiol; 1997 Aug 27; 172(2):209-20. PubMed ID: 9258342
    [Abstract] [Full Text] [Related]

  • 18. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
    Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L, Lindahl U, Hohenester E, Timpl R.
    EMBO J; 1999 Nov 15; 18(22):6240-8. PubMed ID: 10562536
    [Abstract] [Full Text] [Related]

  • 19. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M.
    Eur Cytokine Netw; 2009 Dec 15; 20(4):225-34. PubMed ID: 20167562
    [Abstract] [Full Text] [Related]

  • 20. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives.
    Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, Ribatti D, Rusnati M, Presta M.
    J Biol Chem; 2001 Oct 12; 276(41):37900-8. PubMed ID: 11473122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.